Treatments · 64 clinics in 6 countries · checked 21 Oct 2026
Peptide therapy: evidence, regulation and where it is offered
Peptide therapy uses short chains of amino acids, given by injection, by mouth or on the skin. Our evidence label for it is Unproven. No good evidence of benefit for healthy ageing; regulators have issued warnings or advise against routine use. 64 clinics we list offer it, in the United States, the United Kingdom, Spain, Thailand, the United Arab Emirates and Mexico.
Some peptides are licensed medicines, such as insulin. Others sold by clinics, such as BPC-157, are not approved medicines in Australia or the United States.
What the evidence says
Prescription status: a prescription-only treatment. We show no prices for it where the rules forbid advertising prescription medicines.
Most research on peptides such as BPC-157 has been done in animals, not people (Associated Press, October 2026). In July 2026, staff at the US Food and Drug Administration (FDA) reviewed BPC-157 and three other peptides. They noted a lack of human safety data and recommended that pharmacies should not be allowed to make them up.
Approved peptide medicines, such as insulin, have been tested for specific conditions. That does not show that other peptides help healthy ageing.
Regulators and prescription status
United States. In April 2026 the FDA moved 12 peptides, including BPC-157, out of "category 2", its group of compounding substances that raise significant safety risks. Its page on these substances, updated on 22 April 2026, now lists BPC-157 among nominations that were withdrawn, and keeps its warning that compounded BPC-157 may cause immune reactions for some routes of use. That change alone does not allow pharmacies to make them up. In July 2026 an FDA advisory committee voted in favour of letting pharmacies make up six of the seven peptides it reviewed. The vote is advice to the FDA, not approval. In October 2026 a plan to let pharmacies make some peptides for a time was under White House review and not final.
Australia. The Therapeutic Goods Administration (TGA) says peptides such as BPC-157 are not approved. "Research use only" labels do not make them lawful, and promoting them on social media is likely to break advertising law.
United Kingdom. In April 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) said that peptide injections sold with medical claims are medicines under UK law, and that it will act against clinics that break the rules (Aesthetics Journal).
Unproven means: No good evidence of benefit for healthy ageing; regulators have issued warnings or advise against routine use.
What regulators say
| Country | Note | Source |
|---|---|---|
| United States | In April 2026 the FDA moved BPC-157 and 11 other peptides out of its group of compounding substances that raise significant safety risks, but kept its warning that compounded BPC-157 may cause immune reactions. This alone does not allow pharmacies to make them up. Ask the clinic which products it uses and where they are made. | FDA, compounding substances that may present safety risks, April 2026 |
| United Kingdom | No regulator statement recorded yet. | |
| Spain | No regulator statement recorded yet. | |
| Thailand | No regulator statement recorded yet. | |
| Australia | Peptides such as BPC-157 and TB-500 are not approved in Australia, and the TGA warns that supplying or promoting them is likely to breach the law. | Therapeutic Goods Administration safety alert |
| United Arab Emirates | No regulator statement recorded yet. | |
| Mexico | No regulator statement recorded yet. | |
Where it is offered
Published prices
Prices are not shown in the United Kingdom, Spain, Thailand, the United Arab Emirates and Mexico: it is a prescription-only treatment there.
No price that may be shown is published by the clinics we list.
Safety and questions to ask
The TGA has received reports of severe allergic reactions needing hospital care, and of a body-wide inflammatory reaction, after unapproved peptides. It warns that these products may be contaminated or wrongly labelled, and that injections can cause infection or damage to the skin and tissue around the injection.
- Is the peptide an approved medicine where I live, and who prescribes it?
- Where does the product come from, and was it made by a licensed pharmacy or manufacturer?
- What is it meant to do for me, and how will we know?
- What side effects should I expect, and who do I call?
- Can I take it home through customs, and is it legal where I live?
Sources
- US Food and Drug Administration: certain bulk drug substances for use in compounding that may present significant safety risks
- US Food and Drug Administration: introductory remarks and reviews, Pharmacy Compounding Advisory Committee, 23 July 2026 (PDF)
- Goodwin Procter: FDA signals potentially evolving stance toward compounding of certain peptides, May 2026
- American Med Spa Association: FDA advisory committee recommends adding six of seven peptides to compounding list, July 2026
- Associated Press, via KSAT: administration advances plan for peptide drugs, 15 October 2026
- Therapeutic Goods Administration: understanding your responsibilities when importing, compounding and supplying unapproved peptide products
- Aesthetics Journal: MHRA investigates clinics following peptide claims, 15 April 2026